• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Axsome Therapeutics Inc.

    8/14/25 8:02:41 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AXSM alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)


    Axsome Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    05464T104

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    05464T104


    1Names of Reporting Persons

    RTW Investments, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,516,903.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,516,903.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,516,903.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.1 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    05464T104


    1Names of Reporting Persons

    Roderick Wong
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,516,903.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,516,903.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,516,903.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.1 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Axsome Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    One World Trade Center, 29th Floor, New York, NY, 10007.
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) RTW Investments, LP ("RTW Investments"), a Delaware limited partnership and the investment adviser to certain funds (the "RTW Funds"), with respect to shares of Common Stock, par value $0.0001 per share (the "Shares") of Axsome Therapeutics, Inc. (the "Company") directly held by the RTW Funds; and (ii) Roderick Wong, M.D. ("Dr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.
    (c)Citizenship:

    RTW Investments is a Delaware limited partnership. Dr. Wong is a citizen of the United States.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP No.:

    05464T104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Rows 5 - 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentages set forth in Row 11 of the cover pages are calculated based upon 49,236,365 Shares outstanding as of April 28, 2025 as reported in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 5, 2025.
    (b)Percent of class:

    RTW Investments: 3.1% Dr. Wong: 3.1%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    RTW Investments: 0 Dr. Wong: 0

     (ii) Shared power to vote or to direct the vote:

    RTW Investments: 1,516,903 Shares Dr. Wong: 1,516,903 Shares

     (iii) Sole power to dispose or to direct the disposition of:

    RTW Investments: 0 Dr. Wong: 0

     (iv) Shared power to dispose or to direct the disposition of:

    RTW Investments: 1,516,903 Shares Dr. Wong: 1,516,903 Shares

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2. The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    RTW Investments, LP
     
    Signature:/s/ Roderick Wong, M.D.
    Name/Title:Roderick Wong, M.D., Managing Partner
    Date:08/14/2025
     
    Roderick Wong
     
    Signature:s/ Roderick Wong, M.D.
    Name/Title:Roderick Wong, M.D.
    Date:08/14/2025
    Get the next $AXSM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXSM

    DatePrice TargetRatingAnalyst
    7/3/2025$190.00Overweight
    Morgan Stanley
    6/3/2025$185.00Outperform
    Oppenheimer
    4/7/2025$200.00Buy
    Jefferies
    2/11/2025$176.00Buy
    Deutsche Bank
    12/31/2024$124.00 → $122.00Outperform
    Mizuho
    9/3/2024$140.00Overweight
    Wells Fargo
    8/6/2024$95.00 → $106.00Neutral → Buy
    BofA Securities
    7/22/2024$130.00Buy
    Needham
    More analyst ratings

    $AXSM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Axsome Therapeutics Inc.

    SCHEDULE 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

    8/14/25 8:02:41 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Axsome Therapeutics Inc.

    S-8 - Axsome Therapeutics, Inc. (0001579428) (Filer)

    8/7/25 4:51:58 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Axsome Therapeutics Inc.

    10-Q - Axsome Therapeutics, Inc. (0001579428) (Filer)

    8/4/25 5:21:02 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® 2Q 2025 net product sales of $119.6 million, representing growth of 84% year-over-year and 24% sequentially SUNOSI® 2Q 2025 net product revenue of $30.0 million, representing growth of 35% year-over-year and 19% sequentially SYMBRAVO® launched June 10th, with 2Q 2025 net product sales of $0.4 million AUVELITY® market access expanded by 28 million new covered lives in the commercial channel First group purchasing organization (GPO) contract for SYMBRAVO® signed Supplemental NDA submission for AXS-05 in Alzheimer's disease agit

    8/4/25 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

    Comprehensive review of broad pipeline targeting Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses Presentations by expert clinicians and key opinion leaders Company to webcast its R&D Day event today at 11:00 AM Eastern NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host its Frontiers in Brain Health R&D Day today in New York City to review its industry-leading CNS pipeline. The Frontiers in Brain Health R&D Day will feature presentations from the following six leading

    7/21/25 7:30:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

    NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome's Chief Executive Officer, along with the rest of the management team, and other Axsome team members, will ring the opening bell of the NASDAQ Stock Market today, Monday, July 21, 2025, in connection with its Frontiers in Brain Health R&D Day event being held today. Herriot Tabuteau, MD, Chief Executive Officer of Axsome said, "We are thrilled to ring NASDAQ's opening bell in connection with our Frontiers in Brain Health R&D Day today, showcasing our p

    7/21/25 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $AXSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $AXSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    FDA Approval for AUVELITY issued to AXSOME THERAPEUTICS, INC.

    Submission status for AXSOME THERAPEUTICS, INC.'s drug AUVELITY (ORIG-1) with active ingredient DEXTROMETHORPHAN HYDROBROMIDE AND BUPROPION HYDROCHLORIDE has changed to 'Approval' on 08/18/2022. Application Category: NDA, Application Number: 215430, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    8/19/22 12:36:14 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Murdock Hunter R. exercised 13,514 shares at a strike of $29.91 and sold $1,370,647 worth of shares (13,514 units at $101.42) (SEC Form 4)

    4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

    6/23/25 7:42:47 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Murdock Hunter R. exercised 22,500 shares at a strike of $29.91 and sold $2,276,850 worth of shares (22,500 units at $101.19) (SEC Form 4)

    4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

    6/18/25 9:16:04 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Coleman Mark

    4 - Axsome Therapeutics, Inc. (0001579428) (Issuer)

    6/10/25 7:00:20 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Axsome Therapeutics with a new price target

    Morgan Stanley resumed coverage of Axsome Therapeutics with a rating of Overweight and set a new price target of $190.00

    7/3/25 7:49:15 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Axsome Therapeutics with a new price target

    Oppenheimer initiated coverage of Axsome Therapeutics with a rating of Outperform and set a new price target of $185.00

    6/3/25 7:47:30 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Axsome Therapeutics with a new price target

    Jefferies initiated coverage of Axsome Therapeutics with a rating of Buy and set a new price target of $200.00

    4/7/25 8:43:21 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Leadership Updates

    Live Leadership Updates

    View All

    Axsome Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 7, 2023 deadline.

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 28, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Axsome Therapeutics, Inc. ("Axsome" or "the Company") (NASDAQ:AXSM) investors that a lawsuit filed on behalf of investors that purchased Axsome securities between May 10, 2021 and April 22, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options fo

    11/28/23 6:51:20 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors

    NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Susan Mahony, PhD, has been appointed to Axsome's board of directors, effective immediately. Dr. Mahony most recently served on the board of directors of Horizon Therapeutics from 2019 until its acquisition by Amgen in October 2023. She was formerly Senior Vice President of Eli Lilly and Company and President of Lilly Oncology, where under her leadership, the business unit evolved from one to five marketed medicines. At Lilly, she held leadership position

    10/11/23 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Financials

    Live finance-specific insights

    View All

    Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® 2Q 2025 net product sales of $119.6 million, representing growth of 84% year-over-year and 24% sequentially SUNOSI® 2Q 2025 net product revenue of $30.0 million, representing growth of 35% year-over-year and 19% sequentially SYMBRAVO® launched June 10th, with 2Q 2025 net product sales of $0.4 million AUVELITY® market access expanded by 28 million new covered lives in the commercial channel First group purchasing organization (GPO) contract for SYMBRAVO® signed Supplemental NDA submission for AXS-05 in Alzheimer's disease agit

    8/4/25 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

    NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851 (international). A live webcast of the conference call can be accessed on the "Webcasts & Presentat

    7/9/25 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

    Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI® 1Q 2025 net product revenue of $25.2 million, representing 17% year-over-year growth SYMBRAVO® approved for the acute treatment of migraine; commercial launch on track for June 2025 NDA for AXS-14 for the management of fibromyalgia submitted to the FDA Supplemental NDA submission for AXS-05 in Alzheimer's disease agitation on track for 3Q 2025 NDA submission for AXS-12 for cataplexy in patients with narcolepsy anticipated in 2H 2025 Positive topline results of FOCUS Phase 3 trial of solriamfetol

    5/5/25 7:00:00 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

    SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

    2/14/24 3:46:49 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

    SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

    2/14/24 7:26:39 AM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Axsome Therapeutics Inc. (Amendment)

    SC 13G/A - Axsome Therapeutics, Inc. (0001579428) (Subject)

    2/13/24 4:58:57 PM ET
    $AXSM
    Biotechnology: Pharmaceutical Preparations
    Health Care